Magnesium Glycinate vs L-Threonate vs Oxide: Which Form?

Magnesium Glycinate vs L-Threonate vs Oxide: Which Form?

▶ Watch the video

By Jack Zheng, MS Pharmacy — Founder of MIHIYO Labs

Summary

Magnesium glycinate, L-threonate, and oxide differ more in elemental content and marketing than in benefit. Magnesium oxide is about 60 percent elemental magnesium; one study measured its fractional absorption near 4 percent (Firoz and Graber, 2001), and it also works as an osmotic laxative. Glycinate and L-threonate are more soluble but hold only about 14 and 8 percent elemental magnesium, with little head-to-head data. L-threonate's cognitive claim rests on animal work and small commercially funded trials, two on multi-ingredient formulas. The practical question is usually total elemental magnesium and gut tolerance. A fast-dissolving oral dissolving strip (ODS) cannot practically carry a typical supplemental magnesium dose, so MIHIYO Labs makes none.

Which magnesium form should you actually take?

For closing a dietary magnesium gap, the form matters less than the label math: how much elemental magnesium the product delivers and whether your gut tolerates it. Magnesium glycinate is a reasonable default: a soluble form commonly chosen for gastrointestinal tolerability. Magnesium oxide has shown low fractional absorption in human studies, though its high magnesium density partly offsets that, and it doubles as a laxative. Magnesium L-threonate is the most heavily marketed for brain benefits and the most expensive, and its clinical evidence is small, commercially funded, and thin on independent replication.

I do not formulate with magnesium at MIHIYO, and that is itself part of the answer to this question. Common supplemental doses run into the low hundreds of milligrams of elemental magnesium — far more mass than a thin oral film can hold. So I have read this literature as an outsider to it — deciding what my own family takes, and making sure I was not building a strip around an ingredient whose dose does not fit the format. The three forms below are the ones people ask me about most.

How magnesium form changes absorption

A magnesium supplement is a magnesium ion bound to a carrier — an oxide, an organic acid like citrate, or an amino acid like glycine. Two numbers follow from that pairing. The first is elemental magnesium content: the percentage of the compound's weight that is actually magnesium. Magnesium oxide is small and simple, so it is about 60 percent magnesium by weight. Magnesium glycinate (magnesium bound to two glycine molecules) is about 14 percent. Magnesium L-threonate (magnesium bound to two threonic acid molecules) is about 8 percent. A "1,000 mg magnesium L-threonate" capsule therefore contains only 70 to 80 mg of elemental magnesium; the 2 g daily dose in the 2026 Magtein trial supplied about 145 mg (Lopresti and Smith, 2026)9.

The second number is fractional absorption: the share of the ingested magnesium that crosses the intestinal wall into the blood. Here the carrier matters, mostly through solubility. Magnesium has to be in solution to be absorbed, and magnesium oxide dissolves poorly in the gut. In a 2019 study that screened 15 magnesium products in a gut-simulator model and tested the best and worst in 30 people, the poorly soluble one produced a much smaller four-hour rise in blood magnesium — the concentration-time curve differed by more than an order of magnitude (Blancquaert et al., 2019)4. Solubility predicted absorption.

The most-cited human comparison, Firoz and Graber's 2001 study, measured how much extra magnesium appeared in the urine after volunteers took each of four preparations. A commercial magnesium oxide preparation showed a fractional absorption of about 4 percent, while magnesium chloride, lactate, and aspartate were significantly higher and roughly equivalent to each other (Firoz and Graber, 2001)1. Later work agrees on direction: over 60 days, magnesium citrate and an amino-acid chelate raised 24-hour urinary magnesium more than oxide did in 46 adults (Walker et al., 2003)2, and a single-dose crossover in 20 men found citrate delivered about 0.57 mmol more into 24-hour urine than oxide (Kappeler et al., 2017)3.

Direct human data for glycinate are sparse and do not show a clear absorption edge over oxide: one small crossover trial in ileal-resection patients found similar overall magnesium absorption for magnesium diglycinate and oxide (23.5 versus 22.8 percent), though the chelate did better in the subgroup that absorbed oxide worst, and was better tolerated (Schuette et al., 1994)15. Data for L-threonate are thinner still.

Two cautions on those numbers. Fractional absorption rises when magnesium intake is low and falls when you are replete, so a single-dose study in healthy people may underestimate uptake in someone with low magnesium intake or status. And a poorly absorbed percentage of a magnesium-dense compound still delivers a usable amount — oxide's 60 percent elemental content partly offsets its low fractional absorption. Both points mean the gap between forms is smaller in practice than "4 percent" sounds.

The two steps between a magnesium label and your bloodstream A magnesium supplement's delivered dose is set first by its elemental magnesium content, which ranges from about 8 percent for L-threonate to about 60 percent for oxide, and then by how much of that magnesium is absorbed in the gut, which is low for magnesium oxide. Both steps shrink the number. The label shows the compound weight, not the magnesium that reaches your bloodstream. Compound e.g. 1,000 mg Step 1 Elemental content ~8% threonate ~60% oxide Step 2 Gut absorption low for oxide (~4%, Firoz 2001) Magnesium in the blood

What the three forms compare like

Dimension Magnesium glycinate Magnesium L-threonate Magnesium oxide
Elemental magnesium content ~14% by weight ~8% by weight ~60% by weight
Absorption per gram of compound More soluble than oxide; one small trial found similar overall absorption to oxide (Schuette et al., 199415) Soluble; brain-uptake rationale from animal work, limited human absorption data Low fractional absorption (~4% in one study; Firoz and Graber, 20011), partly offset by high magnesium density
GI effect Often chosen for gastrointestinal tolerability; direct form-specific comparative data limited Generally well tolerated in the trials to date Osmotic laxative; 1.5 g/day improved chronic constipation in 70.6% vs 25.0% on placebo in 34 women (Mori et al., 20197)
Best-supported use Correcting intake gaps; sleep signal is weak (Mah and Pitre, 20216; Schuster et al., 202510) Marketed for cognition; rat data (Slutsky et al., 20105) plus small commercially funded human trials Constipation relief; an inefficient way to raise body magnesium
Human evidence quality Low; few form-specific trials Low; the human RCTs are small, commercially funded, and unreplicated independently Moderate for the laxative effect; long-established
Relative cost per 100 mg elemental Mg Moderate Highest Lowest
Elemental magnesium delivered per 1,000 mg of each compound Every 1,000 mg of magnesium oxide contains about 603 mg of elemental magnesium, versus about 141 mg for magnesium glycinate and about 80 mg for magnesium L-threonate. Gut absorption then reduces the amount that reaches the blood; one study measured only about 4 percent fractional absorption for magnesium oxide. Elemental magnesium per 1,000 mg of compound Magnesium oxide ~603 mg Magnesium glycinate ~141 mg Magnesium L-threonate ~80 mg Then gut absorption cuts these further. One study measured only about 4 percent fractional absorption for magnesium oxide (Firoz and Graber, 2001).

Magnesium glycinate: the sensible default, on thin form-specific data

Magnesium glycinate is magnesium chelated to the amino acid glycine. The rationale for it is tolerability: it is more water-soluble than oxide, and one small study in ileal-resection patients suggested that some magnesium diglycinate may be absorbed as an intact chelate and found it better tolerated than oxide (Schuette et al., 1994)15. That makes glycinate a common everyday choice for people who have had GI trouble with cheaper magnesium — though the head-to-head data behind "less diarrhea than oxide" is thin.

What glycinate does not have is much form-specific clinical evidence. The popular claim that it aids sleep rests mostly on magnesium research that did not use glycinate. A 2021 meta-analysis of three trials in 151 older adults with insomnia found magnesium cut time to fall asleep by about 17 minutes versus placebo, on low-to-very-low-quality evidence (Mah and Pitre, 2021)6. A 2025 trial that did test magnesium bisglycinate — 250 mg elemental magnesium daily for four weeks in 155 adults with poor sleep — found a small, statistically significant improvement in insomnia scores (Cohen's d = 0.2; Schuster et al., 2025)10. Glycinate is a defensible pick for comfort and tolerability; it is not a proven sleep aid.

Magnesium L-threonate: a strong mechanism, small and commercially funded human data

Magnesium L-threonate exists because of one 2010 paper. Researchers developed the compound to raise magnesium levels specifically in the brain and showed it improved learning and memory in rats (Slutsky et al., 2010)5. That mechanism is the entire scientific origin of the "magnesium for your brain" category.

The human evidence is small, uneven, and commercially entangled. Three randomized trials target cognition, and two of them tested multi-ingredient formulas rather than L-threonate alone. A 2016 trial of MMFS-01 (L-threonate plus vitamins C and D) in 44 older adults with cognitive impairment found a 12-week gain on a composite cognition measure, funded by Neurocentria Inc., which co-designed and analyzed it (Liu et al., 2016)11. A 2022 trial of MagteinPS (L-threonate plus phosphatidylserine and vitamins) in 109 healthy adults reported better memory-test scores over 30 days, funded by a Magtein manufacturer (Zhang et al., 2022)12. A 2026 trial of 2 g/day plain Magtein for six weeks in 100 adults reported a marginal cognition-composite edge (both groups improved; interaction p = 0.043) and an estimated "7.5-year" cognitive-age reduction, funded by the maker of the branded ingredient (Lopresti and Smith, 2026)9. Separately, a 2024 sleep trial of 1 g/day L-threonate for 21 days in 80 adults reported better subjective and objective sleep, funded by AIDP Inc., which holds patents on the ingredient and has paid ties to three of the authors; a corrigendum followed (Hausenblas et al., 2024)8. None of these has an independent replication, and L-threonate delivers the least elemental magnesium per gram of the three forms compared here, so it is a poor choice if your goal is simply fixing a magnesium deficit.

Magnesium oxide: a laxative first, a supplement second

Magnesium oxide is cheap, magnesium-dense, and poorly absorbed — which is exactly the profile of an osmotic laxative. The magnesium that stays in the gut draws water into the bowel and speeds transit. In a 2019 randomized, placebo-controlled trial in 34 women with chronic constipation, 1.5 g/day of magnesium oxide produced overall symptom improvement in 70.6 percent versus 25.0 percent on placebo (p = 0.015), and shortened colonic transit time (Mori et al., 2019)7.

For raising body magnesium, oxide is inefficiently absorbed, though its high elemental content means a large enough dose can still contribute meaningful magnesium. If magnesium oxide loosens your stools, that is a sign that enough magnesium is staying unabsorbed in the gut to pull in water.

What this means for MIHIYO's formulations

Magnesium is the clearest example in my ingredient library of a compound whose dose defeats the film format. I hold every MIHIYO formulation to two questions: does the form improve bioavailability or absorption speed for this molecule, and does the effective dose fit a strip that dissolves against the oral mucosa in 30 to 60 seconds? Melatonin passes both — it is active at a fraction of a milligram, which is why the Sleep-Support strip is dosed at the low end of the clinical range for melatonin. Magnesium fails the second test badly. To put 200 mg of elemental magnesium in a strip you would need roughly 330 mg of oxide, 1.4 g of glycinate, or about 2.8 g of L-threonate. Drug-loading capacity is a core limitation of orodispersible films (Borges et al., 2015)13. A frequently cited high-load example, Gas-X Thin Strips, carried 62.5 mg of simethicone per film; more drug raises film thickness and brittleness and prolongs disintegration (Woertz and Kleinebudde, 2015)14. Films suit potent, low-milligram actives. A clinically meaningful magnesium dose needs far more material than a thin, fast-dissolving oral film can practically carry, so I did not build one, and I am skeptical of any strip that claims otherwise.

This is the same reason MIHIYO's mood strip is built from 5-HTP and L-theanine rather than, say, a standardized ashwagandha extract: the ingredients that belong in a strip are the ones that are potent at low milligram doses. Magnesium, ashwagandha extract, and fish oil belong in capsules, powders, or your diet. That the dosage form has to match the molecule cuts both ways — it is also why some ingredients should never be strips.

Where this comparison runs out of evidence

Very few trials compare magnesium forms head to head for a clinical outcome. Most form-versus-form data is single-dose pharmacokinetics in healthy young adults — short-term absorption, not whether eight weeks of one salt raises tissue magnesium more than another. Serum magnesium is a poor readout too: the body holds it in a narrow range, buffered from bone and muscle, so a supplement can work without moving the blood number much.

There is also a funding-related limitation. The forms with the loudest marketing — L-threonate above all — have trials underwritten by the companies selling them, and none has been independently replicated. That does not make the results false, but the confidence interval on "L-threonate makes you sharper" is wider than the marketing implies. When the mechanism is strong and independent human data is thin, the right posture is interest, not conviction.

The bottom line

The practical differences between magnesium glycinate, L-threonate, and oxide are elemental content, gut tolerance, and price — not a large gap in proven benefit. Glycinate is a sensible default for daily use and sensitive stomachs. Oxide is a legitimate laxative and an inefficient way to raise body magnesium. L-threonate has an interesting brain mechanism, but its human evidence is a handful of small, commercially funded trials without independent replication — at the highest cost and the lowest magnesium density of the three. Check the elemental magnesium figure on the label, pick a form your gut tolerates, and treat the cognitive claims as unproven. And if you see magnesium marketed as an oral dissolving strip, do the dose math: the amount that matters does not fit.

References

  1. Firoz M, Graber M. Bioavailability of US commercial magnesium preparations. Magnesium Research. 2001;14(4):257-262. PMID: 11794633. https://pubmed.ncbi.nlm.nih.gov/11794633/
  2. Walker AF, Marakis G, Christie S, Byng M. Mg citrate found more bioavailable than other Mg preparations in a randomised, double-blind study. Magnesium Research. 2003;16(3):183-191. PMID: 14596323. https://pubmed.ncbi.nlm.nih.gov/14596323/
  3. Kappeler D, Heimbeck I, Herpich C, et al. Higher bioavailability of magnesium citrate as compared to magnesium oxide shown by evaluation of urinary excretion and serum levels after single-dose administration in a randomized cross-over study. BMC Nutrition. 2017;3:7. DOI: 10.1186/s40795-016-0121-3. https://doi.org/10.1186/s40795-016-0121-3
  4. Blancquaert L, Vervaet C, Derave W. Predicting and Testing Bioavailability of Magnesium Supplements. Nutrients. 2019;11(7):1663. PMID: 31330811 / DOI: 10.3390/nu11071663. https://pubmed.ncbi.nlm.nih.gov/31330811/
  5. Slutsky I, Abumaria N, Wu LJ, et al. Enhancement of learning and memory by elevating brain magnesium. Neuron. 2010;65(2):165-177. PMID: 20152124 / DOI: 10.1016/j.neuron.2009.12.026. https://pubmed.ncbi.nlm.nih.gov/20152124/
  6. Mah J, Pitre T. Oral magnesium supplementation for insomnia in older adults: a Systematic Review & Meta-Analysis. BMC Complementary Medicine and Therapies. 2021;21(1):125. PMID: 33865376 / DOI: 10.1186/s12906-021-03297-z. https://pubmed.ncbi.nlm.nih.gov/33865376/
  7. Mori S, Tomita T, Fujimura K, et al. A Randomized Double-blind Placebo-controlled Trial on the Effect of Magnesium Oxide in Patients With Chronic Constipation. Journal of Neurogastroenterology and Motility. 2019;25(4):563-575. PMID: 31587548 / DOI: 10.5056/jnm18194. https://pubmed.ncbi.nlm.nih.gov/31587548/
  8. Hausenblas HA, Lynch T, Hooper S, Shrestha A, Rosendale D, Gu J. Magnesium-L-threonate improves sleep quality and daytime functioning in adults with self-reported sleep problems: A randomized controlled trial. Sleep Medicine: X. 2024;8:100121. PMID: 39252819 / DOI: 10.1016/j.sleepx.2024.100121. https://pubmed.ncbi.nlm.nih.gov/39252819/ (Corrigendum: Sleep Medicine: X. 2025;9:100141. PMID: 40567408 / DOI: 10.1016/j.sleepx.2025.100141.)
  9. Lopresti AL, Smith SJ. The effects of magnesium L-threonate (Magtein) on cognitive performance and sleep quality in adults: a randomised, double-blind, placebo-controlled trial. Frontiers in Nutrition. 2026;12. DOI: 10.3389/fnut.2025.1729164. https://doi.org/10.3389/fnut.2025.1729164
  10. Schuster J, Cycelskij I, Lopresti A, Hahn A. Magnesium Bisglycinate Supplementation in Healthy Adults Reporting Poor Sleep: A Randomized, Placebo-Controlled Trial. Nature and Science of Sleep. 2025;17:2027-2040. PMID: 40918053 / DOI: 10.2147/NSS.S524348. https://pubmed.ncbi.nlm.nih.gov/40918053/
  11. Liu G, Weinger JG, Lu ZL, Xue F, Sadeghpour S. Efficacy and Safety of MMFS-01, a Synapse Density Enhancer, for Treating Cognitive Impairment in Older Adults: A Randomized, Double-Blind, Placebo-Controlled Trial. Journal of Alzheimer's Disease. 2016;49(4):971-990. PMID: 26519439 / DOI: 10.3233/JAD-150538. https://pubmed.ncbi.nlm.nih.gov/26519439/
  12. Zhang C, Hu Q, Li S, Dai F, Qian W, Hewlings S, Yan T, Wang Y. A Magtein, Magnesium L-Threonate, -Based Formula Improves Brain Cognitive Functions in Healthy Chinese Adults. Nutrients. 2022;14(24):5235. PMID: 36558392 / DOI: 10.3390/nu14245235. https://pubmed.ncbi.nlm.nih.gov/36558392/
  13. Borges AF, Silva C, Coelho JFJ, Simões S. Oral films: Current status and future perspectives: I - Galenical development and quality attributes. Journal of Controlled Release. 2015;206:1-19. PMID: 25747406 / DOI: 10.1016/j.jconrel.2015.03.006. https://pubmed.ncbi.nlm.nih.gov/25747406/
  14. Woertz C, Kleinebudde P. Development of orodispersible polymer films containing poorly water soluble active pharmaceutical ingredients with focus on different drug loadings and storage stability. International Journal of Pharmaceutics. 2015;493(1-2):134-145. PMID: 26216415 / DOI: 10.1016/j.ijpharm.2015.07.032. https://pubmed.ncbi.nlm.nih.gov/26216415/
  15. Schuette SA, Lashner BA, Janghorbani M. Bioavailability of magnesium diglycinate vs magnesium oxide in patients with ileal resection. JPEN Journal of Parenteral and Enteral Nutrition. 1994;18(5):430-435. PMID: 7815675 / DOI: 10.1177/0148607194018005430. https://pubmed.ncbi.nlm.nih.gov/7815675/

By — Founder of MIHIYO Labs. Focused on the R&D of high-bioavailability, fast-absorption oral dissolving strips.

0 comments

Leave a comment

Please note, comments need to be approved before they are published.